PMID: 7543082Jul 28, 1995Paper

Therapy of human B-cell lymphoma bearing SCID mice is more effective with anti-CD19- and anti-CD38-saporin immunotoxins used in combination than with either immunotoxin used alone

International Journal of Cancer. Journal International Du Cancer
D J FlavellS U Flavell

Abstract

The CD19+ CD38+ human Burkitt's lymphoma cell line Ramos grows aggressively when injected intravenously (i.v.) into severe combined immunodeficient (SCID) mice, killing 100% of animals within a 33-42 day period with widely disseminated disease. Treatment commencing 7 days after i.v. injection of Ramos cells, with 3 doses of an anti-CD19 immunotoxin (IT; BU12-SAPORIN) or an anti-CD38IT (OKT10-SAPORIN) led to a significant prolongation of survival compared with sham-treated controls; the anti-CD38 IT gave the greatest prolongation of survival, but all treated animals eventually succumbed to disease. When both ITs were used in combination at equivalent dose levels, the therapeutic outcome was significantly improved over that obtained for single IT therapy, with 20% of animals surviving disease-free to 300 days. When anti-CD38 IT was given in combination with anti-CD19 antibody there was no therapeutic improvement over anti-CD38 IT used alone. However, when anti-CD19 IT was given in combination with CD38 antibody, a significant prolongation of survival ensued over that obtained with anti-CD19 IT alone, though this was not as significantly pronounced as that obtained when both ITs were used in combination and was only as good as the...Continue Reading

References

Feb 1, 1989·Cellular Immunology·M A de RieF Miedema
Nov 1, 1993·British Journal of Haematology·F M Uckun

❮ Previous
Next ❯

Citations

Dec 13, 2006·Cancer Immunology, Immunotherapy : CII·John F DijosephNitin K Damle
Jun 6, 2000·Advanced Drug Delivery Reviews·I Pastan, R J Kreitman
Nov 10, 2011·Toxins·Letizia PolitoAndrea Bolognesi
Jun 7, 2005·Journal of Controlled Release : Official Journal of the Controlled Release Society·Iring HeislerHendrik Fuchs
Feb 22, 2014·Expert Opinion on Investigational Drugs·Jacob P LaubachKenneth C Anderson
Apr 15, 2004·Biochemical and Biophysical Research Communications·Mark S DuxburyEdward E Whang
Jul 15, 2015·Cancer Research·Nicolas PoretCarl Simon Shelley
Dec 30, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·John F DiJosephNitin K Damle
Apr 10, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Puja Sapra, Theresa M Allen

❮ Previous
Next ❯

Related Concepts

Related Feeds

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.